Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 2.00
CERS's Cash-to-Debt is ranked lower than
66% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. CERS: 2.00 )
Ranked among companies with meaningful Cash-to-Debt only.
CERS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.62  Med: 17.14 Max: 14206.57
Current: 2
0.62
14206.57
Equity-to-Asset 0.38
CERS's Equity-to-Asset is ranked lower than
71% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CERS: 0.38 )
Ranked among companies with meaningful Equity-to-Asset only.
CERS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.06  Med: 0.66 Max: 0.9
Current: 0.38
0.06
0.9
Debt-to-Equity 0.80
CERS's Debt-to-Equity is ranked lower than
62% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. CERS: 0.80 )
Ranked among companies with meaningful Debt-to-Equity only.
CERS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.11 Max: 2.23
Current: 0.8
0
2.23
Debt-to-EBITDA -0.54
CERS's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. CERS: -0.54 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CERS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.54  Med: -0.32 Max: 0
Current: -0.54
-0.54
0
Piotroski F-Score: 3
Altman Z-Score: -6.15
Beneish M-Score: -3.02
WACC vs ROIC
12.79%
-932.46%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -138.33
CERS's Operating Margin % is ranked lower than
53% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. CERS: -138.33 )
Ranked among companies with meaningful Operating Margin % only.
CERS' s Operating Margin % Range Over the Past 10 Years
Min: -390.85  Med: -127.38 Max: -47.15
Current: -138.33
-390.85
-47.15
Net Margin % -140.16
CERS's Net Margin % is ranked lower than
54% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. CERS: -140.16 )
Ranked among companies with meaningful Net Margin % only.
CERS' s Net Margin % Range Over the Past 10 Years
Min: -410.21  Med: -121.75 Max: -43.38
Current: -140.16
-410.21
-43.38
ROE % -126.18
CERS's ROE % is ranked lower than
79% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. CERS: -126.18 )
Ranked among companies with meaningful ROE % only.
CERS' s ROE % Range Over the Past 10 Years
Min: -140.02  Med: -82.23 Max: -56.33
Current: -126.18
-140.02
-56.33
ROA % -64.52
CERS's ROA % is ranked lower than
71% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. CERS: -64.52 )
Ranked among companies with meaningful ROA % only.
CERS' s ROA % Range Over the Past 10 Years
Min: -65.51  Med: -46.82 Max: -33.76
Current: -64.52
-65.51
-33.76
ROC (Joel Greenblatt) % -766.98
CERS's ROC (Joel Greenblatt) % is ranked lower than
58% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. CERS: -766.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CERS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2927.5  Med: -922.65 Max: -501.14
Current: -766.98
-2927.5
-501.14
3-Year Revenue Growth Rate -13.00
CERS's 3-Year Revenue Growth Rate is ranked lower than
67% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CERS: -13.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CERS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -44.5  Med: 0.8 Max: 52.4
Current: -13
-44.5
52.4
3-Year EBITDA Growth Rate -2.60
CERS's 3-Year EBITDA Growth Rate is ranked lower than
56% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. CERS: -2.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CERS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -52.8  Med: 6.1 Max: 127.1
Current: -2.6
-52.8
127.1
3-Year EPS without NRI Growth Rate -1.10
CERS's 3-Year EPS without NRI Growth Rate is ranked higher than
50% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. CERS: -1.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CERS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -30.1  Med: 2.3 Max: 22.7
Current: -1.1
-30.1
22.7
GuruFocus has detected 4 Warning Signs with Cerus Corp CERS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CERS's 30-Y Financials

Financials (Next Earnings Date: 2018-03-07)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

CERS Guru Trades in Q4 2016

Jim Simons 82,000 sh (New)
Ron Baron 282,500 sh (+172.95%)
Chuck Royce 248,000 sh (unchged)
PRIMECAP Management 7,800,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q1 2017

CERS Guru Trades in Q1 2017

Steven Cohen 410,800 sh (New)
Ron Baron 464,300 sh (+64.35%)
Jim Simons 92,500 sh (+12.80%)
PRIMECAP Management 7,800,000 sh (unchged)
Chuck Royce 248,000 sh (unchged)
» More
Q2 2017

CERS Guru Trades in Q2 2017

Paul Tudor Jones 13,506 sh (New)
Ron Baron 560,900 sh (+20.81%)
Chuck Royce 248,000 sh (unchged)
PRIMECAP Management 7,800,000 sh (unchged)
Steven Cohen Sold Out
Jim Simons 80,100 sh (-13.41%)
» More
Q3 2017

CERS Guru Trades in Q3 2017

Jim Simons 560,214 sh (+599.39%)
Ron Baron 560,900 sh (unchged)
PRIMECAP Management 7,800,000 sh (unchged)
Paul Tudor Jones Sold Out
Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CERS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2017-06-30 Add 20.81%$2.02 - $4.61 $ 4.1930%560,900
Ron Baron 2017-03-31 Add 64.35%$3.91 - $4.58 $ 4.19-1%464,300
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2834
Compare:XPAR:ERYP, NAS:CLDX, ROCO:6540, OSTO:ONCO, ASX:SPL, OTCPK:SIGA, NAS:NVAX, TSXV:EMH, NAS:STML, NAS:CRBP, NAS:MRUS, NAS:SNNA, SHSE:603139, TSX:AUP, XKRX:174900, XBRU:CYAD, NAS:ACHN, NAS:MRSN, NAS:INO, NAS:CARA » details
Traded in other countries:CU2.Germany,
Headquarter Location:USA
Cerus Corp is a biomedical products company. It is engaged in developing and commercializing the INTERCEPT Blood System to enhance blood safety.

Cerus Corp is a biomedical products company. It is engaged in developing and commercializing the INTERCEPT Blood System to enhance blood safety.

Guru Investment Theses on Cerus Corp

Baron Funds Comments on Cerus Corp - Jan 20, 2017

Cerus Corporation (NASDAQ:CERS) has an FDA and EU approved device that inactivates pathogens such as viruses and bacteria in donated blood. Current regulatory approvals cover use of the Cerus device for platelets and plasma from donated blood (an $800 million worldwide, and $350 million U.S. market opportunity, for which Cerus has signed up over 80% of all U.S. blood centers). If additional approvals for usage with red blood cell (RBC) components are obtained, Cerus will add an estimated $2.5 billion in market opportunity ($1 billion in the U.S., in the same blood centers), for which there is no current competition. Shares slipped in the fourth quarter as the company slightly extended its timeline (by what we estimate might be one to two quarters) to get the RBC product to market. We believe Cerus is targeting EU approval for RBC in early 2018, and we believe that U.S. approval could be obtained for RBC in 2019. We believe growth prospects for Cerus are significant for 2017 and beyond.



From Baron Discovery Fund's fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Cerus Corp - Feb 25, 2016

Cerus Corporation (NASDAQ:CERS) is a leading provider of medical equipment to the blood banking industry. Its equipment performs pathogen inactivation (PI) on donated blood, preventing infections via transfused blood caused by viruses and bacteria in donated units. Cerus gained significantly in the fourth quarter as it started to gain contracts with a significant number of U.S. blood centers for PI in platelets and plasma. We believe that Cerus has what is likely to be an insurmountable lead in the U.S., and market leading E.U. position for its products. We should see substantial growth for years to come as we expect these markets, which are currently worth about $800 million (for platelets and plasma), could grow to over $3 billion when PI is extended to red blood cell inactivation over the next three to four years.



From Baron Discover Fund's fourth quarter 2015 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Cerus Corp

9 Stocks Ron Baron Keeps Buying The guru increased his position in the last 2 quarters
Ron Baron (Trades, Portfolio) founded Baron Capital Management, an investment management firm. In both the first and second quarters, the guru invested in the following stocks: Read more...
Cerus Corporation (Nasdaq: CERS) to Ring the Nasdaq Stock Market Closing Bell Remotely from the Nasdaq Entrepreneurial Center in San Francisco

Ratios

vs
industry
vs
history
PB Ratio 12.85
CERS's PB Ratio is ranked lower than
72% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CERS: 12.85 )
Ranked among companies with meaningful PB Ratio only.
CERS' s PB Ratio Range Over the Past 10 Years
Min: 0.81  Med: 7.12 Max: 55
Current: 12.85
0.81
55
PS Ratio 9.90
CERS's PS Ratio is ranked higher than
63% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. CERS: 9.90 )
Ranked among companies with meaningful PS Ratio only.
CERS' s PS Ratio Range Over the Past 10 Years
Min: 1.22  Med: 7.6 Max: 21.24
Current: 9.9
1.22
21.24
EV-to-EBIT -7.94
CERS's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. CERS: -7.94 )
Ranked among companies with meaningful EV-to-EBIT only.
CERS' s EV-to-EBIT Range Over the Past 10 Years
Min: -25  Med: -7.4 Max: -0.2
Current: -7.94
-25
-0.2
EV-to-EBITDA -8.20
CERS's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. CERS: -8.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
CERS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -27.9  Med: -7.7 Max: -0.2
Current: -8.2
-27.9
-0.2
EV-to-Revenue 10.18
CERS's EV-to-Revenue is ranked higher than
67% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. CERS: 10.18 )
Ranked among companies with meaningful EV-to-Revenue only.
CERS' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 6.5 Max: 19.7
Current: 10.18
0.4
19.7
Current Ratio 3.71
CERS's Current Ratio is ranked lower than
62% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CERS: 3.71 )
Ranked among companies with meaningful Current Ratio only.
CERS' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 3.82 Max: 9.96
Current: 3.71
1.03
9.96
Quick Ratio 3.11
CERS's Quick Ratio is ranked lower than
64% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. CERS: 3.11 )
Ranked among companies with meaningful Quick Ratio only.
CERS' s Quick Ratio Range Over the Past 10 Years
Min: 1.03  Med: 3.35 Max: 9.96
Current: 3.11
1.03
9.96
Days Inventory 246.25
CERS's Days Inventory is ranked lower than
77% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. CERS: 246.25 )
Ranked among companies with meaningful Days Inventory only.
CERS' s Days Inventory Range Over the Past 10 Years
Min: 122.1  Med: 208.46 Max: 343.01
Current: 246.25
122.1
343.01
Days Sales Outstanding 85.61
CERS's Days Sales Outstanding is ranked lower than
51% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. CERS: 85.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
CERS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.2  Med: 68.27 Max: 256.86
Current: 85.61
44.2
256.86
Days Payable 240.06
CERS's Days Payable is ranked higher than
83% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. CERS: 240.06 )
Ranked among companies with meaningful Days Payable only.
CERS' s Days Payable Range Over the Past 10 Years
Min: 81.15  Med: 127.78 Max: 705.63
Current: 240.06
81.15
705.63

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.90
CERS's 3-Year Average Share Buyback Ratio is ranked higher than
51% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. CERS: -12.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CERS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20.8  Med: -13.3 Max: -6.8
Current: -12.9
-20.8
-6.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 69.83
CERS's Price-to-Net-Cash is ranked lower than
90% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. CERS: 69.83 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CERS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 7.06 Max: 103.13
Current: 69.83
0
103.13
Price-to-Net-Current-Asset-Value 16.76
CERS's Price-to-Net-Current-Asset-Value is ranked lower than
60% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. CERS: 16.76 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CERS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.17  Med: 7.65 Max: 317.86
Current: 16.76
1.17
317.86
Price-to-Tangible-Book 13.52
CERS's Price-to-Tangible-Book is ranked lower than
65% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. CERS: 13.52 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CERS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.92  Med: 7.05 Max: 250
Current: 13.52
0.92
250
Price-to-Median-PS-Value 1.31
CERS's Price-to-Median-PS-Value is ranked higher than
55% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CERS: 1.31 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CERS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.18  Med: 1.22 Max: 69.04
Current: 1.31
0.18
69.04
Earnings Yield (Greenblatt) % -12.60
CERS's Earnings Yield (Greenblatt) % is ranked lower than
73% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. CERS: -12.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CERS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -412  Med: -13.5 Max: -4
Current: -12.6
-412
-4

More Statistics

Revenue (TTM) (Mil) $44.66
EPS (TTM) $ -0.59
Beta1.70
Short Percentage of Float8.81%
52-Week Range $1.93 - 4.70
Shares Outstanding (Mil)115.55

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -0.59 -0.43 -0.27
EPS without NRI ($) -0.59 -0.43 -0.27
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}